TZUR YIGAL, Israel, Sept. 21, 2020 /PRNewswire/ -- BioProtect ltd., a private company with a unique bioabsorbable polymer spacer balloon platform, announced the final closing of $25 million of its ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Olympus said Tuesday it has agreed to buy Israel-based ...

TZUR YIGAL, Israel, Aug. 28, 2023 /PRNewswire/ -- Israeli medical devices manufacturer BioProtect Ltd. announced today that their BioProtect Balloon Implant ™ System has been cleared by the FDA. The ...

Olympus has agreed to acquire BioProtect in a $270m deal, giving the company a commercial device that will help expand its prostate cancer care provision. Israel-based BioProtect’s lead product is ...

TOKYO, May 26, 2026 /PRNewswire/ -- Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, announced today it has signed a definitive agreement to ...

While prostate cancer affects one in eight men, early detection and advanced treatment options mean patients are living longer, healthier lives after diagnosis, according to the American Cancer ...

BioProtect, a company providing biodegradable spacing solutions, recently announced it closed its most recent funding round with $28 million from investors. The round was led by MVM Partners, with ...

Detailed price information for Olympus Corp Ord (OCPNF) from The Globe and Mail including charting and trades.

BioProtect develops implant technologies that contribute to improving prostate cancer care and enhancing patients' quality of life. Its flagship Balloon Spacer system is designed to provide consistent ...